<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575341</url>
  </required_header>
  <id_info>
    <org_study_id>DHEA2000 - V18.03.2003</org_study_id>
    <secondary_id>Vorlagen-Nummer BfArM: 4020260</secondary_id>
    <nct_id>NCT00575341</nct_id>
  </id_info>
  <brief_title>Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency</brief_title>
  <acronym>DHEA2000</acronym>
  <official_title>Dehydroepiandrosterone(DHEA) Substitution in Adolescent and Young Women With Central Adrenal Insufficiency. A Multicenter, Randomised Double Blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      30 adolescent girls and young women between 13 and 26 years with central adrenal
      insufficiency and a grand shortage of DHEA are recruit. The clinical trial is double-blind to
      show that the substitution of the hormone DHEA stimulates secondary hair growth, enhances
      well being and mood of the patients. It should also normalize the serum content of DHEA,
      aldosterone and testosterone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 adolescent girls and young women between 13 and 26 years with central adrenal
      insufficiency and a grand shortage of DHEA are recruit. After randomization they either get
      DHEA or placebo for 12 months daily. The clinical trial is double-blind to show that the
      substitution of the hormone DHEA stimulates secondary hair growth, enhances well being and
      mood of the patients. It should also normalize the serum content of DHEA, aldosterone and
      testosterone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase of pubes as measured by tanner stage</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>enhancement in well being and mood by psychometric tests</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>normalization of the serum content of DHEA, androstanedione and testosterone</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Adrenal Insufficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>substitution of DHEA-hormone, oral, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>substitution of placebo, oral, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dehydroepiandrosterone</intervention_name>
    <description>25 mg DHEA, oral, once daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo, oral, once daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female gender

          -  age between 13 and 26 Years

          -  breast developement minimal Tanner stage 3

          -  serum content of DHEAS less than 400 ng/ml

          -  central hypocortisolism

          -  2 additional pituitary hormon deficiencies (growth hormone, TSH, FSH, LH, prolactin,
             ADH)

          -  no scheduled change of the auxilliary medication during the clinical trial

        Exclusion Criteria:

          -  initial diagnosis of a cerebral tumor less than one year

          -  constitution after cerebral exposure with over 30 gray

          -  craniopharyngioma with hypothalamic defect syndrome or relapse

          -  blindness

          -  mental retardation or psychiatric disorder

          -  systemic disorder, diabetes mellitus, cardiovascular disease, liver disease requiring
             treatment

          -  elevated liver enzyme levels

          -  pregnancy

          -  in case of no hypogonadism: no secure contraception
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Binder, PD Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Children´s Hospital Tuebingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaere Kinderklinik</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik für Kinderheilkunde und Jugendmedizin</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetskinik für Kinder und Jugendliche</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik und Poliklinik für Kinder und Jungendliche</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Miller KK, Sesmilo G, Schiller A, Schoenfeld D, Burton S, Klibanski A. Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab. 2001 Feb;86(2):561-7.</citation>
    <PMID>11158009</PMID>
  </reference>
  <reference>
    <citation>Young J, Couzinet B, Nahoul K, Brailly S, Chanson P, Baulieu EE, Schaison G. Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans. J Clin Endocrinol Metab. 1997 Aug;82(8):2578-85.</citation>
    <PMID>9253337</PMID>
  </reference>
  <reference>
    <citation>Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999 Sep 30;341(14):1013-20.</citation>
    <PMID>10502590</PMID>
  </reference>
  <reference>
    <citation>Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, Herbert J, Chatterjee VK. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab. 2000 Dec;85(12):4650-6.</citation>
    <PMID>11134123</PMID>
  </reference>
  <reference>
    <citation>Johannsson G, Burman P, Wirén L, Engström BE, Nilsson AG, Ottosson M, Jonsson B, Bengtsson BA, Karlsson FA. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab. 2002 May;87(5):2046-52.</citation>
    <PMID>11994339</PMID>
  </reference>
  <reference>
    <citation>Wit JM, Langenhorst VJ, Jansen M, Oostdijk WA, van Doorn J. Dehydroepiandrosterone sulfate treatment for atrichia pubis. Horm Res. 2001;56(3-4):134-9.</citation>
    <PMID>11847477</PMID>
  </reference>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2007</study_first_posted>
  <last_update_submitted>December 17, 2007</last_update_submitted>
  <last_update_submitted_qc>December 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2007</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. med. Gerhard Binder</name_title>
    <organization>University-Children's Hospital Tuebingen, Pediatric Endocrinology</organization>
  </responsible_party>
  <keyword>Central Adrenal Insufficiency</keyword>
  <keyword>DHEA</keyword>
  <keyword>Pubes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

